FGF10 and breast carcinoma: FGF10 stimulation of the ER-positive breast cancer cell line MCF-7 decreases dependency on oestrogen and sensitivity to treatment with anti-oestrogen [159], suggesting that anti-FGF10/FGFR inhibitors can be used to bypass resistance to anti-hormone therapies.